GILD - Gilead touts additional data on liver disease asset seladelpar ahead of PDUFA date
2024-05-20 12:37:35 ET
More on Gilead Sciences
- Biopharma M&A surges year over year in Q1
- Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
- Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
- Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
- Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript